NUCLEOLIN and triple-negative breast carcinoma: This was the rationale underlying the development of the liposomal formulation encapsulating defined ratios of C6-ceramide and DXR, where the functionalization with the nucleolin-binding F3 peptide, and subsequent intracellular delivery, enabled synergistic cell cytotoxicity against the triple-negative breast cancer cells [33].